Showing results (131-140 of 274) with videos related to

Sort By:
Pageof 28
Cancer|April 17, 2014
State of the science in cervical cancer: where we are today and where we need to goDon S Dizon, Helen J Mackay, Gillian M Thomas, et al.
Cancer Chemotherapy and Pharmacology|June 4, 2017
Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancersCody J Peer, Jung-Min Lee, Jeffrey Roth, et al.
Molecular and Clinical Oncology|March 21, 2014
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safetyJohn L Hays, Geoff Kim, Amanda Walker, et al.
Gynecologic Oncology|February 26, 2018
Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting reportStephanie Lheureux, Carolyn McCourt, B J Rimel, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 8, 2017
LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasmaJulia Matsumoto, Brian F Kiesel, Robert A Parise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profilingBen Davidson, Virginia Espina, Seth M Steinberg, et al.
JCO Precision Oncology|October 14, 2022
State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting ReportJosee-Lyne Ethier, Katherine C Fuh, Rebecca Arend, et al.
Cancer|June 22, 2010
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancerChristina M Annunziata, Helene Tuft Stavnes, Lilach Kleinberg, et al.
Molecular Cancer Therapeutics|January 12, 2008
Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancersEllen V Stevens, Satoshi Nishizuka, Smitha Antony, et al.
Cancer Chemotherapy and Pharmacology|February 4, 2010
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi, Dona B Alberti, William R Schelman, et al.
Pageof 28